Bortezomib Ever Pharma

For subcutaneous (SC) administration: Inject into the thigh or abdomen. Rotate injection sites. For intravenous (IV) administration: Administer as a 3-5 second bolus injection into a peripheral or central vein. Do NOT administer intrathecally. Reconstitute lyophilized powder with 0.9% Sodium Chloride Injection.

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins, a process critical for maintaining cellular homeostasis. Inhibition of the proteasome prevents the breakdown of key regulatory proteins, including pro-apoptotic factors, leading to their accumulation and subsequent induction of apoptosis in cancer cells.

• Hypersensitivity to Bortezomib, boron, or mannitol
• Patients with acute diffuse infiltrative pulmonary and pericardial disease

Store intact vials at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from light. Store reconstituted solution at room temperature or refrigerated, protect from light.

No specific antidote for bortezomib overdose. Management involves general supportive measures to treat symptoms and close monitoring of vital signs. Patients may require hospitalization and appropriate medical intervention.

Pregnancy Category D. Can cause fetal harm. Avoid use during pregnancy. Advise women of childbearing potential to use effective contraception during treatment and for a specified period after. It is unknown if bortezomib is excreted in human milk; avoid breastfeeding during treatment and for 2 months after the last dose.